Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I study of R548 in healthy volunteers
NL-OMON37424Phase 1Active, not recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of R548 in autoimmune inflammatory diseases and rheumatoid arthritis (RA) (10 arms), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability. Started Oct 2011; status: active, not recruiting.
02
Drugs
R548
03
Conditions
autoimmune inflammatory diseasesrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON37424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37424.